LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: A versatile magnetic nanocomposite based on cellulose-cyclodextrin hydrogel embedded with graphene oxide and Cu

    Almajidi, Yasir Qasim / Majeed, Ali A / Ali, Eyhab / Abdullaev, Sherzod / Koka, Nisar Ahmad / Bisht, Yashwant Singh / Fenjan, Mohammed N / Alawadi, Ahmed / Alsalamy, Ali / Saleh, Luma Hussain

    International journal of biological macromolecules

    2024  Volume 260, Issue Pt 1, Page(s) 129367

    Abstract: The study focused on creating a novel and environmentally friendly nanocatalyst using cellulose (Cell), β-Cyclodextrin (BCD), graphene oxide (GO), ... ...

    Abstract The study focused on creating a novel and environmentally friendly nanocatalyst using cellulose (Cell), β-Cyclodextrin (BCD), graphene oxide (GO), Cu
    MeSH term(s) Cyclodextrins ; Hydrogels ; Nanoparticles ; Magnetic Phenomena ; Nanocomposites ; Cellulose ; Graphite
    Chemical Substances Cyclodextrins ; graphene oxide ; Hydrogels ; Cellulose (9004-34-6) ; Graphite (7782-42-5)
    Language English
    Publishing date 2024-01-12
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 282732-3
    ISSN 1879-0003 ; 0141-8130
    ISSN (online) 1879-0003
    ISSN 0141-8130
    DOI 10.1016/j.ijbiomac.2024.129367
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2374: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Long non-coding RNA (lncRNA) PVT1 in drug resistance of cancers: Focus on pathological mechanisms.

    Jasim, Saade Abdalkareem / Majeed, Ali A / Uinarni, Herlina / Alshuhri, Mohammed / Alzahrani, Abdullah Ali / Ibrahim, Abeer A / Alawadi, Ahmed / Abed Al-Abadi, Noor K / Mustafa, Yasser Fakri / Ahmed, Batool Ali

    Pathology, research and practice

    2024  Volume 254, Page(s) 155119

    Abstract: According to estimates, cancer will be the leading cause of death globally in 2022, accounting for 9.6 million deaths. At present, the three main therapeutic modalities utilized to treat cancer are radiation therapy, chemotherapy, and surgery. However, ... ...

    Abstract According to estimates, cancer will be the leading cause of death globally in 2022, accounting for 9.6 million deaths. At present, the three main therapeutic modalities utilized to treat cancer are radiation therapy, chemotherapy, and surgery. However, during treatment, tumor cells resistant to chemotherapy may arise. Drug resistance remains a major oppose since it often leads to therapeutic failure. Furthermore, the term "acquired drug resistance" describes the situation where tumor cells already display drug resistance before undergoing chemotherapy. However, little is still known about the basic mechanisms underlying chemotherapy-induced drug resistance. The development of new technologies and bioinformatics has led to the discovery of additional genes associated with drug resistance. Long noncoding RNA plasmacytoma variant translocation 1 (PVT1) has been linked to an increased risk of cancer, according to a growing body of research. Apart from biological functions associated with cell division, development, pluripotency, and cell cycle, lncRNA PVT1 contributes significantly to the regulation of various aspects of genome function, such as transcription, splicing, and epigenetics. The article will address the mechanism by which lncRNA PVT1 influences drug resistance in cancer cells.
    MeSH term(s) Humans ; Cell Line, Tumor ; Cell Proliferation ; Gene Expression Regulation, Neoplastic/genetics ; MicroRNAs/genetics ; Neoplasms/genetics ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism ; Drug Resistance, Neoplasm
    Chemical Substances MicroRNAs ; RNA, Long Noncoding ; PVT1 long-non-coding RNA, human
    Language English
    Publishing date 2024-01-11
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 391889-0
    ISSN 1618-0631 ; 0344-0338
    ISSN (online) 1618-0631
    ISSN 0344-0338
    DOI 10.1016/j.prp.2024.155119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud III Zs.20: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Therapeutic gene delivery by mesenchymal stem cell for brain ischemia damage: Focus on molecular mechanisms in ischemic stroke.

    Saleh, Raed Obaid / Majeed, Ali A / Margiana, Ria / Alkadir, Ola Kamal A / Almalki, Sami G / Ghildiyal, Pallavi / Samusenkov, Vadim / Jabber, Noura Kareem / Mustafa, Yasser Fakri / Elawady, Ahmed

    Cell biochemistry and function

    2024  Volume 42, Issue 2, Page(s) e3957

    Abstract: Cerebral ischemic damage is prevalent and the second highest cause of death globally across patient populations; it is as a substantial reason of morbidity and mortality. Mesenchymal stromal cells (MSCs) have garnered significant interest as a potential ... ...

    Abstract Cerebral ischemic damage is prevalent and the second highest cause of death globally across patient populations; it is as a substantial reason of morbidity and mortality. Mesenchymal stromal cells (MSCs) have garnered significant interest as a potential treatment for cerebral ischemic damage, as shown in ischemic stroke, because of their potent intrinsic features, which include self-regeneration, immunomodulation, and multi-potency. Additionally, MSCs are easily obtained, isolated, and cultured. Despite this, there are a number of obstacles that hinder the effectiveness of MSC-based treatment, such as adverse microenvironmental conditions both in vivo and in vitro. To overcome these obstacles, the naïve MSC has undergone a number of modification processes to enhance its innate therapeutic qualities. Genetic modification and preconditioning modification (with medications, growth factors, and other substances) are the two main categories into which these modification techniques can be separated. This field has advanced significantly and is still attracting attention and innovation. We examine these cutting-edge methods for preserving and even improving the natural biological functions and therapeutic potential of MSCs in relation to adhesion, migration, homing to the target site, survival, and delayed premature senescence. We address the use of genetically altered MSC in stroke-induced damage. Future strategies for improving the therapeutic result and addressing the difficulties associated with MSC modification are also discussed.
    MeSH term(s) Humans ; Ischemic Stroke/metabolism ; Brain Ischemia/therapy ; Brain Ischemia/metabolism ; Stroke/therapy ; Stroke/metabolism ; Ischemic Preconditioning/methods ; Mesenchymal Stem Cells/metabolism ; Mesenchymal Stem Cell Transplantation
    Language English
    Publishing date 2024-03-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 283643-9
    ISSN 1099-0844 ; 0263-6484
    ISSN (online) 1099-0844
    ISSN 0263-6484
    DOI 10.1002/cbf.3957
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1994: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Overcoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers.

    Kadhum, Wesam R / Majeed, Ali A / Saleh, Raed Obaid / Ali, Eyhab / Alhajlah, Sharif / Alwaily, Enas R / Mustafa, Yasser Fakri / Ghildiyal, Pallavi / Alawadi, Ahmed / Alsalamy, Ali

    Pathology, research and practice

    2024  Volume 255, Page(s) 155137

    Abstract: Metastatic cancer, which accounts for the majority of cancer fatalities, is a difficult illness to treat. Currently used cancer treatments include radiation therapy, chemotherapy, surgery, and targeted treatment (immune, gene, and hormonal). The ... ...

    Abstract Metastatic cancer, which accounts for the majority of cancer fatalities, is a difficult illness to treat. Currently used cancer treatments include radiation therapy, chemotherapy, surgery, and targeted treatment (immune, gene, and hormonal). The disadvantages of these treatments include a high risk of tumor recurrence and surgical complications that may result in permanent deformities. On the other hand, most chemotherapy drugs are small molecules, which usually have unfavorable side effects, low absorption, poor selectivity, and multi-drug resistance. Anticancer drugs can be delivered precisely to the cancer spot by encapsulating them to reduce side effects. Stimuli-responsive nanocarriers can be used for drug release at cancer sites and provide target-specific delivery. As previously stated, metastasis is the primary cause of cancer-related mortality. We have evaluated the usage of nano-medications in the treatment of some metastatic tumors.
    MeSH term(s) Humans ; Drug Resistance, Neoplasm ; Neoplasms/drug therapy ; Antineoplastic Agents/pharmacology ; Drug Resistance, Multiple
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2024-01-14
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 391889-0
    ISSN 1618-0631 ; 0344-0338
    ISSN (online) 1618-0631
    ISSN 0344-0338
    DOI 10.1016/j.prp.2024.155137
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud III Zs.20: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top